Mahaffey KW, et al. - Given that canagliflozin attenuates renal failure risk in patients with type 2 diabetes and chronic kidney disease, researchers explored its impacts on specific cardiovascular outcomes as well as in those without prior cardiovascular disease (primary prevention). Participants (n=4,401) were patients with type 2 diabetes and chronic kidney disease. In a random manner, these patients received canagliflozin or placebo with optimized standard of care. Relative to secondary prevention participants (N=2,220; 50.4%), the primary prevention participants (N=2181; 49.6%) had younger age, shorter diabetes duration, and were more often female. In patients with type 2 diabetes and chronic kidney disease, including those without prior cardiovascular disease, a significant reduction in major cardiovascular events and kidney failure was evident in relation to treatment with canagliflozin.